Bone and joint health markers in persons with hemophilia A treated with emicizumab in the HAVEN 3 clinical trial
Objective: Multiple factors contribute to bone health, including physical activity, lifestyle, diet, and certain medical conditions. Emicizumab prophylaxis has been shown to reduce the frequency of bleeding episodes in persons…
Redefining Treatment Satisfaction and Its Impact on Treatment Adherence and Value for Persons with Hemophilia: Findings from the HemACTIVE Study
Assessing and Responding to the Oral Health Care Needs of Adults in a Bleeding Disorders Population
Introduction/Background: Maintenance of oral health is frequently challenging for US adults with a bleeding disorder. Underlying causes are due mainly to (1) lack of dental insurance and (2) lack of knowledge among dentists about…
Retrospective review of Hemophilia patients before and after treatment with Emicizumab
Objectives: The longer-term clinical outcomes of patients using emicizumab in real world settings are not well documented. This study examined hemophilia patient clinical outcomes, specifically bleed rate, emergency room visits/…
The Moti-VIII Study – Factors for Empowering Mobility and Well-being in Hemophilia A
Unmet Needs in Women with Severe Von Willebrand Disease
Objective: Women with Severe Von Willebrand disease (VWD), including Type 3 VWD, Severe Type 1/1C VWD (VWF ristocetin cofactor and antigen ≤10%), and Severe Type 2A (VWF ristocetin cofactor and antigen ≤10%) are at high risk for…
Characterization of the Early Immune Response to Factor VIII
Behavior and cognition in children and young adults with hemophilia A or B: an update on developmental outcome
The 2020 World Federation of Hemophilia Guidelines for the Management of Hemophilia
A Novel Approach for Rare Bleeding Disorders: Shielded Living Therapeutics